 Life Science Investor Mandates
(Sept. 29
- Oct. 5)
|
|
|
|
Invests in Growth Stage Medtech and HCIT
|
Seeks Partnerships in Inflammation and Dermatology Drugs and Surgical Devices
|
|
Invests in Early Stage Devices, Therapeutics, and Diagnostics
|
|
Invests in Approved Devices for China Market
|
|
Click to see investors that are a fit for your product and stage of development
|
|
Click here if you are a service provider and want to see a list of funded life science companies that are a fit for you
|
|
Click here if you want to receive free, targeted early stage dealflow for your life science investment firm
|
|
|
|
Organizing RESI Partnering was an amazing experience for me, and with the help of Alisdair Stamps from Meeting-Mojo, RESI Boston successfully had more than 1,300 meetings.
Now, I would like to remove the curtains as the Wizard of Oz or RESI and share a few tips on what I learned about partnering and getting meetings with investors.
Investor Profiles Are Filled Out in Depth
I have been to many partnering conferences and rarely see investor profiles filled out besides the name of the attendee representing the firm. A strong differentiator of the RESI Conferences is LSN's ability to populate investor profiles with their up-to-date investment preferences and criteria. The reason for this is to help fundraising companies make the most of their time by meeting with the right investors...
|
 |
|
|
The healthcare investment world is just over 90 days out from the annual San Francisco conference week, and investors are already inking their plans for a busy week. Within that hectic JPM ecosystem, RESI SF is a key venue to meet with early stage startups, and many investors are already made their plans to attend.
LSN would like to make our first RESI San Francisco panel announcement: Healthcare IT Investors. This panel focuses on investors that are looking for innovative startups using software to solve healthcare problems, from drug discovery and development to care provision and management. Significant investment is pouring into this sector, with an estimated $4.5 billion invested in 2015. At RESI, we'll hear from 5 highly active investors from a diverse variety of firms on what they're looking for in healthcare IT at present, and how an opportunity can catch their attention.
The participants will be:
- Edward Kliphuis, Investment Director, Merck Ventures
- Momei Qu, Vice President, Baird Venture Partners
- Akhil Saklecha, Partner, Artiman Ventures
- David Kim, CEO, DigiTx Partners
- Lana Ghanem, Managing Director, Hikma Ventures
|
|
|
By Nono Hu, Director of Marketing, LSN
Hot off the press in September, LSN's partners at Venture Valuation have created a report on life science financing round data from around the world.
This free report summarises every recorded round that took place in August, and provides summaries of the investment sizes, stages and the hottest areas for life science investment, along with highlights of the most significant financings.
This information is based on reports from dozens of bioclusters worldwide, in addition to the work of a team of analysts focused on early stage life science startups. Subscribers to the LSN Company Platform can access all this information directly...
|
|
|
